Erasca, Inc. (ERAS)

NASDAQ: ERAS · IEX Real-Time Price · USD
2.970
+0.160 (5.69%)
At close: Jul 12, 2024, 4:00 PM
3.000
+0.030 (1.01%)
After-hours: Jul 12, 2024, 7:54 PM EDT
5.69%
Market Cap 771.74M
Revenue (ttm) n/a
Net Income (ttm) -126.86M
Shares Out 259.85M
EPS (ttm) -0.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 5,271,759
Open 2.860
Previous Close 2.810
Day's Range 2.790 - 3.100
52-Week Range 1.510 - 3.100
Beta 1.16
Analysts Strong Buy
Price Target 6.00 (+102.02%)
Earnings Date Aug 8, 2024

About ERAS

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 16, 2021
Employees 126
Stock Exchange NASDAQ
Ticker Symbol ERAS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ERAS stock is "Strong Buy." The 12-month stock price forecast is $6.0, which is an increase of 102.02% from the latest price.

Price Target
$6.0
(102.02% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Erasca to Present at Upcoming Investor Conferences in June

SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...

6 weeks ago - GlobeNewsWire

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...

7 weeks ago - GlobeNewsWire

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors

2 months ago - GlobeNewsWire

Erasca Announces Pricing of Underwritten Offering of Common Stock

SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...

2 months ago - GlobeNewsWire

Erasca Reports First Quarter 2024 Business Updates and Financial Results

Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and exist...

2 months ago - GlobeNewsWire

Erasca to Present at the Bank of America Health Care Conference

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...

2 months ago - GlobeNewsWire

Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting

Oral presentation will feature updated HERKULES-3 results for ERK1/2 inhibitor ERAS-007 in combination with encorafenib and cetuximab in BRAFm colorectal cancer

2 months ago - GlobeNewsWire

Erasca Announces $45 Million Oversubscribed Private Placement Financing

Funding from new and existing investors extends anticipated cash runway into H2 2026 Funding from new and existing investors extends anticipated cash runway into H2 2026

3 months ago - GlobeNewsWire

Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801

3 months ago - GlobeNewsWire

Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...

6 months ago - GlobeNewsWire

Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma

First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safet...

7 months ago - GlobeNewsWire

Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway

Gained alignment with global health authorities for pivotal Phase 3 SEACRAFT-2 trial design for naporafenib plus trametinib in NRAS mutant melanoma; initiation on track for H1 2024

8 months ago - GlobeNewsWire

Erasca Reports Third Quarter 2023 Financial Results and Business Updates

First patient dosed in SEACRAFT-1 Phase 1b trial evaluating naporafenib plus trametinib Multiple upcoming catalysts across ongoing clinical programs Strong balance sheet with cash, cash equivalents, a...

8 months ago - GlobeNewsWire

Erasca to Present at Upcoming Investor Conferences in November

SAN DIEGO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...

8 months ago - GlobeNewsWire

Erasca to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...

11 months ago - GlobeNewsWire

Erasca Doses First Patient in SEACRAFT-1 Phase 1b Trial Evaluating Naporafenib Plus Trametinib in Patients with RAS Q61X Solid Tumors

Anti-tumor activity in patients with NRAS Q61X melanoma and KRAS Q61X NSCLC supports tissue agnostic development in RAS Q61X solid tumors

11 months ago - GlobeNewsWire

Erasca Reports Second Quarter 2023 Financial Results and Business Updates

Significant progress across all clinical programs including Phase 1b combo data for ERAS-007 and ERAS-601, FTD and ODD granted for ERAS-801, and publication of naporafenib combination data

1 year ago - GlobeNewsWire

Erasca Granted FDA Orphan Drug Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 for the Treatment of Malignant Glioma

ERAS-801 has now received ODD in addition to FDA Fast Track Designation Initial THUNDERBBOLT-1 Phase 1 monotherapy data in patients with recurrent GBM expected in H2 2023 SAN DIEGO, June 22, 2023 (GLO...

1 year ago - GlobeNewsWire

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class ERK inhibit...

1 year ago - GlobeNewsWire

Erasca to Present at Upcoming Investor Conferences

SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for p...

1 year ago - GlobeNewsWire

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

The virtual event will take place on Monday, June 5, 2023, at 4:30 PM ET The virtual event will take place on Monday, June 5, 2023, at 4:30 PM ET

1 year ago - GlobeNewsWire

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation ...

1 year ago - GlobeNewsWire

Erasca Further Strengthens Business Leadership with Two Key Promotions

David Chacko, M.D., previously Erasca's Chief Financial Officer, has been promoted to the dual position of Chief Financial Officer and Chief Business Officer

1 year ago - GlobeNewsWire

Erasca Reports First Quarter 2023 Financial Results and Business Updates

Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal Phase 3 SEACRAFT-2 trial for naporafenib in patients with NRASm melanoma expected to initiate in H1 20...

1 year ago - GlobeNewsWire

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for pa...

1 year ago - GlobeNewsWire